Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Dan You, Stephen Hillerman, Gregory Locke, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 1, pp. e001402-e001402
Open Access | Times Cited: 61

Showing 26-50 of 61 citing articles:

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
Lin Yang, Qiuling Zhao, Ting Chen, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 7, pp. 3767-3780
Closed Access | Times Cited: 9
Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors
Siyu Fu, Jiakuan Wei, Chunting Li, et al.
Bioorganic Chemistry (2024) Vol. 148, pp. 107454-107454
Closed Access | Times Cited: 3
Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation
M. Ahn, Eun Hye Kim, Yunha Choi, et al.
PLoS ONE (2024) Vol. 19, Iss. 6, pp. e0305261-e0305261
Open Access | Times Cited: 3
Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1
John C. Tellis, BinQing Wei, Michael Siu, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 9, pp. 1606-1614
Closed Access | Times Cited: 3
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer
Jingjing Peng, Xiaoyu Ding, Celia Y. Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Deep Generation Model Guided by the Docking Score for Active Molecular Design
Yuwei Yang, Chang‐Yu Hsieh, Yu Kang, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 10, pp. 2983-2991
Closed Access | Times Cited: 8
Discovery of quinazoline HPK1 inhibitors with high cellular potency
Momar Toure, Theresa Johnson, Bin Li, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 92, pp. 117423-117423
Closed Access | Times Cited: 8
Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling
Shenxin Zeng, Yuyuan Jin, Heye Xia, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 107016-107016
Closed Access | Times Cited: 8
High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients
Jingxin Zhang, Ziyuan Ren, Yun Hu, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111363-111363
Closed Access | Times Cited: 8
Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion
Shenxin Zeng, Ming Zeng, Shuai Yuan, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106728-106728
Closed Access | Times Cited: 7
Ginsenosides: an immunomodulator for the treatment of colorectal cancer
Jianan Qian, Yanyu Jiang, Hongyi Hu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
Huizhen Ge, Lizeng Peng, Zhou Sun, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors
Qinda Ye, Kai Liu, Hai‐Fen Ye, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 14, Iss. 1, pp. 5-10
Open Access | Times Cited: 9
Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors
Junjie Zhang, Yan Li, Haotian Tang, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106811-106811
Closed Access | Times Cited: 5
Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1)
Wai Leung Lau, Bradley C. Pearce, Heather Malakian, et al.
Acta Crystallographica Section F Structural Biology Communications (2020) Vol. 77, Iss. 1, pp. 22-28
Open Access | Times Cited: 14
Cuproptosis scoring model predicts overall survival and assists in immunotherapeutic decision making in pancreatic carcinoma
Tijun Liu, Qing Liu, Yongju Wang, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 8
Breaking the mold: Overcoming resistance to immune checkpoint inhibitors
Menglu Zhao, Chunyan Yan, Ya-Nan Wei, et al.
Antiviral Research (2023) Vol. 219, pp. 105720-105720
Closed Access | Times Cited: 4
Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy
Zhimin Zhang, Liubin Guo, Mengting Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18682-18698
Closed Access | Times Cited: 1
Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors
Jingjing Peng, Xiaoyu Ding, Celia Y. Chen, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 2032-2041
Closed Access | Times Cited: 1
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti‐Solid Tumor Immunity
Yuejun Yao, Mingfei Wu, Yanfang Wang, et al.
Advanced Materials (2024)
Closed Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies
Kyriakos P. Papadopoulos, Scott A. Laurie, Alexander I. Spira, et al.
Regular and Young Investigator Award Abstracts (2023), pp. A835-A835
Open Access | Times Cited: 3
A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses
Michael Agrez, Justyna Rzepecka, Darryl Turner, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia
Hua Wang, Rohan Moniruzzaman, Lei Li, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 12
Open Access | Times Cited: 2
Colorectal Cancer and Immunity: From the Wet Lab to Individuals
Élodie Pramil, Clémentine Dillard, Alexandre E. Escargueil
Cancers (2021) Vol. 13, Iss. 7, pp. 1713-1713
Open Access | Times Cited: 5

Scroll to top